Sufficiency of explained: this guide covers what it means, who it applies to, the step-by-step process, documents required, fees, due dates and penalties in India — so you can stay compliant with confidence and avoid costly mistakes.
Paragraph 11 of the Pharmaceutical Patent Guidelines (October 2014) is the drafting paragraph for drug applications. It explains what the description must contain to be sufficient, how the claims must be supported, how Markush groups and functional claims are treated, and how disclosure of biological material works, with four examples of claims broader than their examples.
The description must let a skilled person carry out substantially all that is claimed without undue experimentation, with examples or test data covering the full breadth of the claims (11.6, 11.8). Claims must be clear and fairly based on the description (11.12). Functional claims are discouraged (11.13) and Markush groups need a technical interrelationship between the alternatives (11.14, 11.15). Sufficiency and support are different tests that complement each other (Example 1). The Guidelines are the Patent Office's guidance and do not have the force of law; the Patents Act, 1970 and the Patents Rules, 2003 as now in force prevail.
The Office revises its guidelines, so check the current version on ipindia.gov.in. This document dates from October 2014 and cites an IPAB decision; the IPAB has since been abolished and appeals now go to the High Court (see our post on IPAB dissolution). The statutory source is section 10; see section 10, claims, abstract and biological material. For the same ground in the Manual, read our article on sufficiency and unity. A pharmaceutical specification can be reviewed against this paragraph through patent drafting and filing.
What the examiner reads against (paragraphs 11.1 and 11.10)
The Guidelines recall that section 10(4)(a) and (b) require a full and particular description, including the method of performing the invention that the applicant considers most suitable, that section 10(4)(c) requires claims, and that section 10(5) requires claims to be clear, succinct and fairly based on the description and to relate to a single inventive concept. The sufficiency requirements and the clarity and support requirements are complementary and are to be examined together (11.10).
Sufficiency of description (paragraphs 11.4 to 11.9)
| Paragraph | What the Guidelines say | What it means for the draft |
|---|---|---|
| 11.4 | Claims for things not identified at filing but findable by carrying out the applicant's process are not patentable for insufficiency, as in claiming many compounds without support in the examples; the description must describe an embodiment of each claim and enable those in the industry to carry it out without further invention | Every claim needs a worked embodiment behind it |
| 11.5 | The whole subject matter claimed, not only a part, must be capable of being carried out by a skilled person without undue experimentation or inventive ingenuity | Do not claim beyond what the examples support |
| 11.6 | The person addressed for enablement has average skill and knowledge, per an IPAB ruling as cited; at least one example covering the full breadth; for a product, examples for all compounds claimed or at least all genera; preparation methods and property data for representatives of each embodiment | Examples must span the genus |
| 11.7 | Trade marks and other non-technical terms should be replaced with technical terms | Use technical names |
| 11.8 | The relevant date is the date of the complete specification; test reports, in vitro or in vivo, with parameters, choice of method, mode of delivery, results, explanation and inference must be in the description for a substance, composition or combination; representative tests for each genus and use claimed | The data should be in the specification, not only in later evidence |
| 11.9 | The process by which a new compound was discovered need not be described in the claims where it is common knowledge in the science | No need to claim well-known discovery routes |
For the person skilled in the art, the Guidelines cite Raj Prakash v Mangat Ram Chowdhry and Farbwerke Hoechst v Unichem Laboratories as cited, and the IPAB's Enercon v Aloys Wobben for the distinction between the person for obviousness and the person for enablement.
Biological material and the source of origin (paragraphs 11.2 and 11.3)
Where the invention involves a biological material that cannot be described sufficiently and is not available to the public, the application is completed by deposit with an International Depository Authority under the Budapest Treaty. The Guidelines say the deposit is to be made not later than the filing date in India, with a reference to the deposit in the specification within three months of filing, and the specification must carry the characteristics needed to identify the material and the name and address of the depository and the date and number of the deposit. The period agrees with our post on rule 13(8), which also records a proviso tied to a request for early publication; the rule post prevails.
On source and geographical origin, the Guidelines incorporate the Traditional Knowledge Guidelines: where biological material is used and its source and geographical origin are not disclosed, an objection is raised under section 10(4); and where the applicant cancels the Form 1 declaration of use of Indian material and states the material is not from India, the specification is amended to say so at the start with the country of source. The Guidelines describe the Biological Diversity Act as it stood in 2014, and the Form 1 was substituted in 2024; the Act as amended in 2023 and the current form should be checked (see our post on the forms as substituted in 2024).
Clarity and support of claims (paragraphs 11.11 to 11.15)
- Use claims (11.11). Claims in the form "use of ..." are not permissible: a claim must be to a product or a process.
- Lack of support (11.12). A claim lacks support if it is not fairly based on the description, if it is much broader than the description and enablement, or if it uses terms such as "comprising" or "approximately" in a way that leaves the scope unclear; such terms are examined against the description.
- Functional claims (11.13). Claims defining substances by physiological properties or results are discouraged as they confuse scope, are nearly always much wider and are inconsistent with the description.
- Markush groups (11.14, 11.15). Special care is needed. The alternatives must have a technical interrelationship. Where one claim defines alternatives, this is met when they are of a similar nature: all share a common property or activity, and either a significant common structural element or, where structure cannot unify them, membership of a recognised class of compounds. Claims are linked by a single inventive concept where they are related by a common thread, such as a drug, its intermediates and the process of making them; intermediates are allowed if new and non-obvious and no other use is disclosed.
The four examples (paragraph 11.16)
| Example | The Guidelines' scenario | Objection | Reason |
|---|---|---|---|
| 1 | A generic formula with several choices for the first substituent, while all the examples fix it as phenyl | Lack of support, and sufficiency may also be raised | The claim is much broader than what is described and enabled; sufficiency and support are different criteria that supplement each other |
| 2 | An H2 receptor antagonist defined as an open-ended combination of "substituted" groups, with examples limited to a few substituents | Insufficiency and lack of support | Open-ended terms cover many compounds that would not serve the purpose, and the examples cannot enable other classes |
| 3 | An insecticidal compound formula with variables; the examples support only one sub-formula where one atom is oxygen; the activity is not demonstrated | Section 10(4)(a) (no evidence of the claimed use) and 10(4)(b) (the sulphur analogues and their preparation are not disclosed) | The disclosure is not sufficient for the whole scope |
| 4 | A cancer compound formula with broad groups, where the examples cover four specific compounds with preparation and assay | Lack of support for the broad groups | Preparing the other compounds and finding their activity would need undue experimentation |
What the examiner checks, and what to file
| Examiner's question | What the applicant should show |
|---|---|
| Is there an embodiment for each claim? | Worked examples, covering the genus, with preparation methods |
| Is the use shown? | Test results (in vitro or in vivo) in the description, with parameters and inference |
| Is each Markush alternative related? | A common property and a common structure or recognised class |
| Is the claim broader than the examples? | Claims narrowed to what the examples support, or further examples within the original specification |
| Is there biological material? | Deposit details and source and origin statement |
A worked example (invented)
Kalyani Therapeutics claims a family of compounds with a variable group defined as "any substituted aryl or heteroaryl group", while its examples all have a phenyl ring with a halogen. The examiner objects under paragraph 11.16 Example 1 and 4 for lack of support and insufficiency. Kalyani limits the claim to phenyl rings with one to three halogen substituents, which its tests cover, and files a divisional for other aromatic groups only if its original specification contains support. The reply narrows to match the data and does not rely on an assertion that the skilled person could extend the examples.
Common lapses
- Claiming a genus on the strength of a handful of examples.
- Placing test data in an affidavit but not in the specification.
- Using open terms such as "substituted" or "derivatives" without limits.
- Claiming a compound by its result ("a compound that inhibits X").
Need help with a sufficiency or support objection?
The fix is nearly always a claim set that matches the examples and data in the specification as filed. Our team can map your claims to your disclosure and prepare the reply. See patent drafting and filing, and read next on unity of invention under paragraph 12.
Key takeaways
- The description must enable substantially all that is claimed, with examples across the genus.
- Test data should be in the description at the filing date.
- Functional and "use of" claims are discouraged or not permitted.
- Markush alternatives need a common property and a common structure or recognised class.
- Sufficiency and support are separate but complementary tests.
Read next
- Pharmaceutical Patent Guidelines 2014, paragraphs 1 to 6: scope, claims and search
- Pharmaceutical Patent Guidelines 2014, paragraph 12: unity of invention
- Manual Chapter 9: sufficiency of disclosure and unity of invention
- Section 10 of the Patents Act, 1970: claims, abstract and biological material
Disclaimer: Based on the manuals and guidelines published by the Office of the Controller General of Patents, Designs and Trade Marks that are named in the article, as consulted on 4 October 2026. They are guidance and do not have the force of law; the Patents Act, 1970 and the Patents Rules, 2003 as amended (including the 2024 amendment rules) prevail, and the current versions on ipindia.gov.in should be checked. This article is general information, not legal advice; check the official text before acting.